Drug
Hydrochlorothiazide 12.5mg
Hydrochlorothiazide 12.5mg is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_4
2
50%
Ph early_phase_1
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Active, not recruiting1
Completed1
unknown1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (33.3%)
Phase 42 (66.7%)
Trials by Status
active_not_recruiting125%
completed125%
unknown125%
withdrawn125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingearly_phase_1
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
NCT04676399
unknownphase_4
Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy
NCT04242758
withdrawnphase_4
Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
NCT03640221
completed
Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use
NCT01050062
Clinical Trials (4)
Showing 4 of 4 trials
NCT04676399Early Phase 1
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
NCT04242758Phase 4
Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy
NCT03640221Phase 4
Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
NCT01050062
Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4